Basket | Login | Register


P13. Neuronet: From risk, to dementia – Understanding disease progression and its causes

Detailed programme and abstracts

Abstract will be available soon

P13.1. ADAPTED - Alzheimer's disease apolipoprotein pathology for treatment elucidation and development



P13.2. IMPRiND - Inhibiting misfolded protein propagation in neurodegenerative diseases

TOFARIS George1, VOLBRACHT Christiane2, on behalf of the IMPRiND Consortium  

1University of Oxford, Oxford, United Kingdom, 2Lundbeck, Copenhagen, Denmark

A growing body of data indicates that the propagation of pathogenic protein aggregates across neural systems could be mediated by misfolded protein seeds that are released and taken up by anatomically connected neurons causing disruption of their function. Therefore, blocking the propagation of misfolded tau and α-synuclein may help arrest the progression of Alzheimer’s or Parkinson’s disease.

The IMPRiND Consortium, funded by the Innovative Medicine Initiative (IMI), is a group of European academic laboratories and members of the European Federation of Pharmaceutical Industries and Associations (EFPIA) that aims to delineate and target critical steps in the propagation of α-synuclein and tau assemblies between neurons. Our collaborative programme and mobilizes diverse expertise to perform high throughput screens and deliver pathophysiologically relevant phenotypes suitable for validation of identified targets in cellular systems of increasing complexity as well as animal models.

We will present an overview of our methodological approach and progress towards clinical translation.

P13.3. PHAGO - Inflammation and AD: modulating microglia function - Focussing on TREM2 and CD33

EBNETH Andreas


P13.4. AETIONOMY - Organising mechanistic knowledge about neurodegenerative diseases for the improvement of drug development and therapy

HOFMANN-APITIUS Martin1, SCHNEIDER Reinhard2, FORGÓ Nikolaus3, CORVOL Jean-Christophe4, CARNARD Luc5, FRÖHLICH Holger6, SCORDIS Phil7 and the AETIONOMY consortium 

1Fraunhofer Institute for Algorithms and Scientific Computing (SCAI), Sankt Augustin, Germany, 2Université du Luxembourg, Belvaux, Luxembourg, 3University of Vienna, Vienna, Austria, 4Institut du Cerveau et de la Moelle (ICM), Paris, France, 5Sanofi, Chilly-Mazain CEDEX, France, 6UCB BioPharma, Monheim, Germany, 7UCB BioPharma, Slough, United Kingdom

The AETIONOMY project was initiated to pave the way for a “mechanism-based taxonomy for neurodegenerative diseases”. The generation of such a “mechanism-based taxonomy” is an extremely ambitious undertaking, as neurodegenerative diseases are widely known as “idiopathic diseases”, which means that the disease etiology is unknown.

Over the project runtime of 5 years, the AETIONOMY consortium has implemented a big data approach that delivered not only the proof-of-concept that a mechanism-based taxonomy for neurodegenerative diseases is possible, but also a broad spectrum of resources, which are of highest value for ongoing and future research on neurodegeneration. AETIONOMY has generated the largest inventory of knowledge-based, computable disease mechanism representations for Alzheimer´s disease and Parkinsonism worldwide. It has furthermore developed the text analytics machinery to keep these computable models of disease up to date. Moreover, in the course of the project we developed the algorithmic basis for modeling and mining that associates disease mechanisms with (longitudinal) patient-level data. All these resources were made freely accessible and usable to the scientific community. The clinical work package has recruited its own Parkinsonism – cohort and in close collaboration between data scientists and clinical researchers, we could demonstrate that defined candidate mechanism have the potential to identify patient subgroups in this cohort and an independent control cohort.

AETIONOMY has paved the way for future stratification of patients according to underlying disease mechanisms (or combination of disease mechanisms). As the first project of this kind, AETIONOMY has successfully demonstrated that an approach that tries to make all public knowledge and all public data in a given indication area interoperable and amenable for modeling and mining, is possible.

More than that: AETIONOMY has also shown that the substantial investment in this effort is well justified, as it leads to meaningful results.

P13.5. PRISM - Psychiatric Ratings using Intermediate Stratified Markers: Providing quantitative biological measures to facilitate the discovery and development of new treatments for social and cognitive deficits in AD, SZ, and MD


United Kingdom



Last Updated: Friday 16 August 2019


  • Acknowledgements

    The 29th AE Conference in The Hague received funding under an operating grant from the European Union’s Health Programme (2014-2020). Alzheimer Europe and Alzheimer Nederlands gratefully acknowledge the support of all conference sponsors.
  • European Union
  • Roche